Thomas Gallaher, MD
Infectious Disease · Greenville, NCNPI 1235450453
Payments from drug & device makers
Across 444 payments — averaging $349.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$101K
- AbbVie$33K
- Merck$9K
- Insmed, Inc.$7K
- Astellas Pharma US Inc$2K
- Melinta Therapeutics, LLC$808
- plus $2K from 31 others
What the payments were for
- Consulting fees$6,7394%
- Speaking & faculty fees$125,61281%
- Travel & lodging$14,7539%
- Food & beverage$7,7075%
- Education$4770%
- Gifts$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 157 | $101,107 |
| AbbVie(2 entities) | 88 | $32,893 |
| Merck | 36 | $8,967 |
| Insmed, Inc. | 19 | $7,248 |
| Astellas Pharma US Inc | 14 | $1,931 |
| Melinta Therapeutics, LLC | 6 | $808 |
| Viiv Healthcare Company | 24 | $637 |
| Novo Nordisk | 19 | $246 |
| Amgen | 15 | $212 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $132 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $127 |
| Shionogi Inc | 1 | $117 |
| Lilly USA, LLC | 6 | $106 |
| Janssen Products, LP | 1 | $100 |
| Johnson & Johnson(2 entities) | 6 | $89 |
| Abbott | 3 | $67 |
| Dynavax Technologies Corporation | 5 | $55 |
| GSK | 3 | $54 |
| Grifols USA, LLC | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Boehringer Ingelheim | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Angiodynamics, Inc. | 1 | $15 |
| CSL Behring | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Beckman Coulter, Inc. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Cumberland Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,300 in reported general payments places this provider in the 85th percentile of 250 infectious disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 109 | $489,845 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 27 | $411,924 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $183,591 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 14 | $150,506 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 37 | $150,326 |
| DovatoDolutegravir Sodium/Lamivudine | 38 | $115,880 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 23 | $89,913 |
| DescovyEmtricitabine/Tenofov Alafenam | 36 | $79,645 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $59,962 |
| Isentress HdRaltegravir Potassium | 29 | $57,470 |
| Daptomycin | 141 | $55,099 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $55,081 |
| ErtapenemErtapenem Sodium | 79 | $32,282 |
| Meropenem | 71 | $23,231 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 86 | $12,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $101,107 | $659,402168 claims |
| Insmed, Inc.Arikayce | $7,248 | $411,92427 claims |
| CSL BehringHizentra | $15 | $183,59125 claims |
| PfizerPanzyga | $16 | $150,50614 claims |
| Viiv Healthcare CompanyDovato | $637 | $115,88038 claims |
| Grifols USA, LLCGamunex-C | $46 | $59,96213 claims |
| MerckIsentress Hd | $8,967 | $57,47029 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $45 | $55,08117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 infectious disease providers in North Carolina.
Other infectious disease in Greenville
- Paul CookGreenville$2.9M
- Rabindra GhimireGreenville$15K
- Alexandra StangGreenville$12K
- John SandersWinston Salem$5.2M
- Cristina GasparettoDurham$3.2M
- Susanna NaggieDurham$2.7M
- John SandersWilmington$2.4M
- Mitchell HorwitzDurham$2M
- Cornelius van DamGreensboro$2M
- Frederick CruickshankHuntersville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.